An investigation into the expression and mechanism of action of urotensin II in chronic pressure-overloaded rat hearts

Liu,Wenyuan; Han,Qinghua; Liu,Qinghua; Liang,Gang; Wang,Jin; Liu,Chengfang

doi:10.3892/mmr.2015.4244

An investigation into the expression and mechanism of action of urotensin II in chronic pressure-overloaded rat hearts

Authors:
- Wenyuan Liu
- Qinghua Han
- Qinghua Liu
- Gang Liang
- Jin Wang
- Chengfang Liu
View Affiliations

Affiliations: Department of Cardiology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China, Teaching and Research Department of Pathophysiology, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China, Department of Pathology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China, Teaching and Research Department of Physiology, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China
Published online on: August 25, 2015 https://doi.org/10.3892/mmr.2015.4244
Pages: 6626-6634
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the role and mode of action of urotensin II (U II) in the occurrence and progression of cardiac fibrosis in a pressure‑overload rat model. Coarctation of the abdominal aorta was used to establish an animal model, and postoperative echocardiography, hemodynamic detection, hematoxylin and eosin staining, Masson staining and immunohistochemistry were performed to assess the changes in cardiac function and pathology. The expression levels of U II, G‑protein‑coupled receptor 14 and collagen (Col) I and Col III in the myocardial tissues were also analyzed. Neonatal rat fibroblasts were isolated, cultured and subsequently, generations 3‑5 were randomly divided into different groups for the detection of Col I and Col III levels by enzyme‑linked immunosorbent assay and western blotting. The protein expression levels were markedly increased in the model group, and this increase correlated with an increase in myocardial fibrosis. In cultured neonatal rat fibroblast cells, 10‑8 mol/l U II significantly stimulated the synthesis of Col I and Col III (P<0.01) compared with the control group. Compared with the U II group, the administration of KT5720 (1 mol/l) or SB‑611812 (1 mol/l) significantly reduced the synthesis and expression levels of Col I and Col III (P<0.05). U II may exert an important role in the process of myocardial fibrosis in chronic pressure‑overload rats, and the cyclic adenosine monophosphate‑protein kinase A signaling pathway may be partly involved in this process.

View Figures

View References

1	Ross B, McKendy K and Giaid A: Role of urotensin II in health and disease. Am J Physiol Regul Integr Comp Physiol. 298:R1156–R1172. 2010. View Article : Google Scholar : PubMed/NCBI
2	Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, et al: Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 401:282–286. 1999. View Article : Google Scholar : PubMed/NCBI
3	Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, Kimura Y, Sasano H and Murakami O: Role of urotensin II in patients on dialysis. Lancet. 358:810–811. 2001. View Article : Google Scholar : PubMed/NCBI
4	Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N and Hirata Y: Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens. 19:2185–2190. 2001. View Article : Google Scholar : PubMed/NCBI
5	Ban Y, Watanabe T, Suguro T, Matsuyama TA, Iso Y, Sakai T, Sato R, Idei T, Nakano Y, Ota H, et al: Increased plasma urotensin-II and carotid atherosclerosis are associated with vascular dementia. J Atheroscler Thromb. 16:179–187. 2009. View Article : Google Scholar : PubMed/NCBI
6	Chen Z, Xu J, Ye Y, Li Y, Gong H, Zhang G, Wu J, Jia J, Liu M, Chen Y, et al: Urotensin II inhibited the proliferation of cardiac side population cells in mice during pressure overload by JNK-LRP6 signalling. J Cell Mol Med. 18:852–862. 2014. View Article : Google Scholar : PubMed/NCBI
7	Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE and Krum H: Direct actions of urotensin II on the heart: Implications for cardiac fibrosis and hypertrophy. Circ Res. 93:246–253. 2003. View Article : Google Scholar : PubMed/NCBI
8	Shi L, Ding W, Li D, Wang Z, Jiang H, Zhang J and Tang C: Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis. 188:260–264. 2006. View Article : Google Scholar
9	Zhang YG, Li J, Li YG and Wei RH: Urotensin II induces phenotypic differentiation, migration, and collagen synthesis of adventitial fibroblasts from rat aorta. J Hypertens. 26:1119–1126. 2008. View Article : Google Scholar : PubMed/NCBI
10	Zhao J, Ding W, Song N, Dong X, Di B, Peng F and Tang C: Urotensin II-induced collagen synthesis in cultured smooth muscle cells from rat aortic media and a possible involvement of transforming growth factor-β1/Smad2/3 signaling pathway. Regul Pept. 182:53–58. 2013. View Article : Google Scholar : PubMed/NCBI
11	Bousette N, Pottinger J, Ramli W, Ohlstein EH, Dhanak D, Douglas SA and Giaid A: Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides. 27:2919–2926. 2006. View Article : Google Scholar : PubMed/NCBI
12	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. 8th edition. National Academies Press; Washington (DC): 2011
13	Ma L, Liu J, Chu N, et al: The relationship between cardiac hypertrophy index and cardiac function in chronic heart failure rats. J Capit Med Univ (Chin). 31:596–599. 2010.
14	Kehat I and Molkentin JD: Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation. 122:2727–2735. 2010. View Article : Google Scholar : PubMed/NCBI
15	Berenji K, Drazner MH, Rothermel BA and Hill JA: Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol. 289:H8–H16. 2005. View Article : Google Scholar : PubMed/NCBI
16	Creemers EE and Pinto YM: Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res. 89:265–272. 2011. View Article : Google Scholar
17	Bayer AL, Heidkamp MC, Patel N, Porter MJ, Engman SJ and Samarel AM: PYK2 expression and phosphorylation increases in pressure overload-induced left ventricular hypertrophy. Am J Physiol Heart Circ Physiol. 283:H695–H706. 2002. View Article : Google Scholar : PubMed/NCBI
18	Lapp H, Boerrigter G, Costello-Boerrigter LC, Jaekel K, Scheffold T, Krakau I, Schramm M, Guelker H and Stasch JP: Elevated plasma human urotensin-II-1ike immunoreactivity in ischemic cardiomyopathy. Int J Cardiol. 94:93–97. 2004. View Article : Google Scholar : PubMed/NCBI
19	Russell FD, Meyers D, Galbraith AJ, Bett N, Toth I, Kearns P and Molenaar P: Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol. 285:H1576–H1581. 2003. View Article : Google Scholar : PubMed/NCBI
20	Tran L, Kompa AR, Kemp W, Phrommintikul A, Wang BH and Krum H: Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats. Am J Physiol Heart Circ Physiol. 298:H608–H613. 2010. View Article : Google Scholar
21	Dai HY, Kang WQ, Wang X, Yu XJ, Li ZH, Tang MX, Xu DL, Li CW, Zhang Y and Ge ZM: The involvement of transforming growth factor-beta1 secretion in urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts. Regul Pept. 140:88–93. 2007. View Article : Google Scholar
22	Dai HY, He T, Li XL, Xu Wl and Ge ZM: Urotensin-2 promotes collagen synthesis via ERK1/2-dependent and ERK1/2-independent TGF-β1 in neonatal cardiac fibroblasts. Cell Biol Int. 35:93–98. 2011. View Article : Google Scholar
23	Domínguez-Rodríguez A, Díaz I, Rodríguez-Moyano M, Calderón-Sánchez E, Rosado JA, Ordóñez A and Smani T: Urotensin-II signaling: Mechanism in rat coronary artery: Role of STIM1 and Orai1-dependent store operated calcium influx in vasoconstriction. Arterioscler Thromb Vasc Biol. 32:1325–1332. 2012. View Article : Google Scholar
24	Song QG, Lü JZ and Yang JX: Effect of urotensin II on the proliferation of cardiac Myofibroblasts and its intracellular signaling mechanism in new-born SD rats. J Xi'an Jiaotong Univ. 28:157–160. 2007.
25	Kemp W, Kompa A, Phrommintikul A, Herath C, Zhiyuan J, Angus P, McLean C, Roberts S and Krum H: Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats. Am J Physiol Gastrointest Liver Physiol. 297:G762–G767. 2009. View Article : Google Scholar : PubMed/NCBI
26	Rossowski WJ, Cheng BL, Taylor JE, Datta R and Coy DH: Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: Inhibition by somatostatin receptor antagonists. Eur J Pharmacol. 438:159–170. 2002. View Article : Google Scholar : PubMed/NCBI
27	Zhang YG, Li YG, Liu BG, Wei RH, Wang DM, Tan XR, Bu DF, Pang YZ and Tang CS: Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacol Sin. 28:36–43. 2007. View Article : Google Scholar
28	Staudt Y, Mobini R, Fu M, Felix SB, Kühn JP and Staudt A: Beta1-adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes. Eur J Pharmacol. 466:1–6. 2003. View Article : Google Scholar : PubMed/NCBI
29	Li CJ and Han QH: Effect of Urotensin II on cardiac function in heart failure rats and its mechanism of action. Chinese J Integr Med Cardio Cerebrovasc Dis. 6:38–40. 2008.
30	Han QH, Liu WY, Li CJ, Wang R and Shi HT: The effect of urotensin II on cardiac function of rats and its electrophysiological mechanism. Chinese J Integr Med Cardio Cerebrovasc Dis. 9:1479–1481. 2011.